"10.1371_journal.pone.0115270","plos one","2015-02-18T00:00:00Z","Julian P Halcox; Florence Tubach; Esther Lopez-Garcia; Guy De Backer; Claudio Borghi; Jean Dallongeville; Eliseo Guallar; Jesús Medina; Joep Perk; Ogün Sazova; Stephen Sweet; Carine Roy; José R Banegas; Fernando Rodriguez-Artalejo","Institute of Life Sciences 2, Swansea University College of Medicine, Swansea, United Kingdom; INSERM CIC-EC 1425 and Epidemiology and Clinical Research Department, Assistance Publique—Hôpitaux de Paris, Hôpital Bichat, Paris, France; Univ Paris Diderot, Sorbonne Paris Cité, UMR 1123, Paris, France; Department of Preventative Medicine and Public Health, Universidad Autónoma de Madrid IdiPaz and CIBERESP, Madrid, Spain; Department of Public Health, University of Ghent, Ghent, Belgium; Department of Internal Medicine, Ageing and Clinical Nephrology, University of Bologna, Bologna, Italy; INSERM U 744, Institut Pasteur de Lille, Université Lille-Nord de France, Lille, France; Departments of Epidemiology and Medicine and Welch Center of Prevention, Epidemiology and Clinical Research, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States of America; Department of Cardiovascular Epidemiology and Population Genetics, National Center for Cardiovascular Research, Madrid, Spain; Observational Research Centre, Global Medical Affairs, AstraZeneca Farmacéutica Spain, Madrid, Spain; School of Health and Caring Sciences, Linnaeus University, Kalmar, Sweden; AstraZeneca Global Medical Affairs, London, United Kingdom; Research Evaluation Unit, Oxford PharmaGenesis Ltd, Oxford, United Kingdom","Conceived and designed the experiments: JH FT ELG GDB CB JD EG JM JP OS CR JB FRA. Performed the experiments: JH FT ELG GDB CB JD EG JM JP OS CR JB FRA. Analyzed the data: FT CR JH. Wrote the paper: JH FT ELG GDB CB JD EG JM JP OS SS CR JB FRA.","The authors have the following interests. Julian P. Halcox and Jean Dallongeville have received speaker and consulting fees from AstraZeneca. Florence Tubach and Eliseo Guallar have received research funding from AstraZeneca. Stephen Sweet is an employee of Oxford PharmaGenesis Ltd, which has received funding from AstraZeneca. Jesús Medina and Ogün Sazova are employees of AstraZeneca. The EURIKA study was funded by a commercial source (AstraZeneca). Writing support was provided by Oxford PharmaGenesis Ltd, Oxford, UK, and was funded by AstraZeneca. The rest of the authors declare that they have no competing interests. There are no patents, products in development or marketed products to declare. This does not alter the authors′ adherence to all the PLOS ONE policies on sharing data and materials, as detailed online in the guide for authors.","2015","02","Julian P Halcox","JPH",14,FALSE,13,13,3,14,TRUE,TRUE,FALSE,0,NA,FALSE
